Explore

Rapid Read Rapid Read
FDA Grants Expanded Access to Experimental Pancreatic Cancer Drug, Offering Hope to Patients

FDA Grants Expanded Access to Experimental Pancreatic Cancer Drug, Offering Hope to Patients

The Food and Drug Administration (FDA) has granted 'expanded access' to a promising pancreatic cancer drug, daraxonrasib, allowing it to be administered to a broader group of patients while it is still under regulatory review. This decision comes in response to an application from the drug's manufacturer, Revolution Medicines, and was approved just two days after submission. The FDA's swift action underscores the urgent need for effective treatments for pancreatic cancer, which is known for its high mortality rate. Daraxonrasib has shown promising results in clinical trials, doubling the average survival time for patients who have already undergone conventional treatments. The expanded access program, also known as 'compassionate use,' will be available to patients who meet specific criteria, and the drug will be provided at no cost to them.
Rapid Read Rapid Read
FDA Grants Expanded Access to Experimental Pancreatic Cancer Drug for Wider Patient Use

FDA Grants Expanded Access to Experimental Pancreatic Cancer Drug for Wider Patient Use

The Food and Drug Administration (FDA) has announced the granting of 'expanded access' to a promising pancreatic cancer drug, allowing it to be administered to a broader group of patients while it is still under regulatory review. This decision comes in response to an application from Revolution Medicines, the manufacturer of the drug, known as daraxonrasib. The FDA's action is aimed at addressing the urgent need for effective treatments for pancreatic cancer, which is one of the most lethal forms of cancer. The expanded access program, also referred to as 'compassionate use,' will be available to patients who have already undergone conventional treatment. Revolution Medicines has committed to providing the drug at no cost to eligible patients, as insurance typically does not cover drugs that have not yet received full approval.
Rapid Read Rapid Read
FDA Grants Expanded Access to Experimental Pancreatic Cancer Drug

FDA Grants Expanded Access to Experimental Pancreatic Cancer Drug

The Food and Drug Administration (FDA) has granted expanded access to an experimental pancreatic cancer drug, daraxonrasib, developed by Revolution Medicines. This decision allows a broader group of patients to receive the drug while it is still under regulatory review. The FDA's action underscores the urgent need for effective treatments for pancreatic cancer, one of the deadliest forms of cancer. Daraxonrasib has shown promise in clinical trials, doubling the average survival time for patients who have already undergone conventional treatment. The expanded access program, also known as compassionate use, will provide the drug at no cost to eligible patients, although insurance typically does not cover such drugs before approval.
Reuters Reuters
US FDA authorizes early access to Revolution's pancreatic cancer pill

US FDA authorizes early access to Revolution's pancreatic cancer pill

May 1 (Reuters) - The U.S. Food and Drug Administration has authorized the granting of early access before regulatory approval to Revolution Medicines’ pill for patients with previously treated pancreatic cancer, the company said on Friday.
Trendline Trendline
FDA Advisory Committee Recommends Against AstraZeneca's Breast Cancer Drug Approval

FDA Advisory Committee Recommends Against AstraZeneca's Breast Cancer Drug Approval

FDA Advisory Committee Recommends Against AstraZeneca's Breast Cancer Drug Approval
Trendline Trendline
FDA Approves Axsome's Auvelity for Alzheimer's Agitation, Marking a First

FDA Approves Axsome's Auvelity for Alzheimer's Agitation, Marking a First

FDA Approves Axsome's Auvelity for Alzheimer's Agitation, Marking a First
Rapid Read Rapid Read
FDA Advisory Committee Recommends TRUQAP for PTEN-Deficient Prostate Cancer

FDA Advisory Committee Recommends TRUQAP for PTEN-Deficient Prostate Cancer

The FDA's Oncologic Drugs Advisory Committee has recommended AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) for treating PTEN-deficient metastatic hormone-sensitive prostate cancer. The recommendation is based on the CAPItello-281 Phase III trial, which demonstrated a favorable benefit-risk profile for the drug combination. The trial showed a significant reduction in the risk of disease progression and improved survival outcomes for patients. This marks the first targeted treatment combination to show benefits in this specific subtype of prostate cancer, addressing a significant unmet need for patients with limited treatment options.
Trendline Trendline
FDA's ODAC Delivers Mixed Results for AstraZeneca's Cancer Treatments

FDA's ODAC Delivers Mixed Results for AstraZeneca's Cancer Treatments

FDA's ODAC Delivers Mixed Results for AstraZeneca's Cancer Treatments
Trendline Trendline
FDA Panel Delivers Mixed Verdict on AstraZeneca's Cancer Drugs

FDA Panel Delivers Mixed Verdict on AstraZeneca's Cancer Drugs

FDA Panel Delivers Mixed Verdict on AstraZeneca's Cancer Drugs
Rapid Read Rapid Read
FDA Advisory Committee to Review AstraZeneca's Cancer Drug Applications Amid Concerns

FDA Advisory Committee to Review AstraZeneca's Cancer Drug Applications Amid Concerns

The FDA is set to hold its first drug-related advisory committee meeting in nine months to evaluate AstraZeneca's applications for two cancer drugs. The meeting will focus on the oral SERD drug camizestrant for HR-positive, HER2-negative breast cancer and the AKT inhibitor Truqap for metastatic hormone-sensitive prostate cancer. The FDA has raised questions about the clinical benefits and trial designs of these drugs, particularly regarding the validity of results and the timing of treatment interventions. The advisory panel will assess whether AstraZeneca has provided sufficient evidence to support the clinical benefits of these drugs.
Trendline Trendline
Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy

Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy

Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy
Trendline Trendline
Pfizer's ELREXFIO Shows Promising Results in Multiple Myeloma Treatment

Pfizer's ELREXFIO Shows Promising Results in Multiple Myeloma Treatment

Pfizer's ELREXFIO Shows Promising Results in Multiple Myeloma Treatment